Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 pilot study of topical clobetasol 0.05% mucosal formulation in mucous membrane pemphigoid
2021-001826-23Phase 2Completed
- Sponsor
- Università degli Studi di Firenze
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of clobetasol in cicatricial pemphigoid (CP), sponsored by Università degli Studi di Firenze. Primary endpoint: Safety of the product. Started Oct 2022; status: completed.
02
Drugs
clobetasol
03
Conditions
cicatricial pemphigoid (CP)
Beyond the preview
Go deeper on 2021-001826-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001826-23.